





RealRate

PHARMACEUTICAL 2023

AgeX Therapeutics Inc.
Rank 416 of 446



The relative strengths and weaknesses of AgeX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AgeX Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 31% points. The greatest weakness of AgeX Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 186% points.

The company's Economic Capital Ratio, given in the ranking table, is -339%, being 382% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,453
Cost of Goods Sold	13
Intangible Assets	738
Liabilities, Current	10,078
Liabilities, Non-Current	0
Other Assets	50
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	10,478
Other Net Income	-3,547
Other Revenues	34
Property and Equipment	0
Research and Development	1,025
Selling, General and Administrative Expense	5,971

Output Variable	Value in 1000 USD
Assets	3,241
Liabilities	20,556
Expenses	7,009
Revenues	34
Stockholders Equity	-17,315
Net Income	-10,522
Comprehensive Net Income	-10,522
Economic Capital Ratio	-339%